Medical News Today -
5 Nov 2013 12:00
Gilead Sciences, Inc. (Nasdaq: GILD) has announced results from a Phase 3 study, PHOTON-1, evaluating the investigational once-daily nucleotide analogue inhibitor sofosbuvir for the treatment of chronic hepatitis C virus (HCV) infection among patients co-infected with HIV. In the trial, 76 percent (n=87/114) of genotype 1 HCV treatment-naïve patients receiving 24 weeks of an all-oral, interferon-free regimen of sofosbuvir plus ribavirin (RBV) achieved a sustained virologic response 12 weeks a...
Share this Article